Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

February 25, 2026 - 04:41

Cosmos Health Inc. has significantly strengthened its strategic guidance with the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board. The globally recognized expert will focus his efforts on advancing the Company's biotechnology initiatives, particularly in the cutting-edge fields of AI-driven drug discovery and clinical-stage therapeutic development.

Dr. Iliopoulos brings a formidable reputation and deep expertise in leveraging artificial intelligence to revolutionize the process of identifying and developing new medicines. His appointment signals Cosmos Health's committed expansion into innovative biotech ventures, aiming to integrate advanced computational methods with traditional healthcare services. The move is seen as a strategic step to accelerate the pipeline of novel treatments and enhance the Company's position in the competitive healthcare landscape.

Company leadership expressed strong enthusiasm about the collaboration, highlighting Dr. Iliopoulos's proven track record and thought leadership as invaluable assets. They believe his insights will be crucial for navigating the complexities of modern drug development, potentially leading to more efficient and targeted therapies. This advisory board addition aligns with Cosmos Health's broader vision of creating a diversified, vertically integrated healthcare group capable of delivering solutions from research and development to patient care.